Keywords
How to Cite
Abstract
The aim of the research was to study the relationship between plasma concentrations of resistin and indicators of enzyme and pigment metabolism in patients with non-alcoholic fatty liver disease (NAFLD) and its combination with type 2 diabetes mellitus (DM-2).
Materials and methods. On the base of Kharkiv Regional Hospital a total of 90 patients were examined, including patients with NAFLD (n = 20) and its combination with DM-2 with normal body weight (n = 20) and obesity (n = 50), as well as 20 healthy volunteers. A complex of clinical, laboratory and instrumental (including liver biopsy in 9 patients) examinations of patients was performed.
Results. A direct relationship was established between the level of resistin and indicators of enzyme and pigment exchange in groups of patients with combined pathology. A significant increase of resistin plasma level, as well as disorders of the liver function were determined in all groups of patients in comparison with the controls. The most marked changes were revealed in patients with combination of NAFLD, DM-2 and obesity.
Conclusions. The established relationship between the level of resistin and the indicators of the liver functional state suggests that an increase of resistin level may reflect the presence of impaired liver function in patients with NAFLD in combination with DM-2, predicting the progression of NAFLD. In order to detect the disorders of liver function in patients with DM-2, it is recommended to determine the level of resistin in patients with NAFLD, especially when concomitant obesity is present. Patients with resistin level (> 8.06 ± 0.23 ng/ml) should be considered at risk of NAFLD progression.
References
References
Drapkina O.M., Korneeva O.N. (2016). Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Ration pharmacother cardiol,12(4), 424-429.
Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. (2018). Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol, 24, 3361-73.
Younes R, Bugianesi E. (2019). NASH in lean individuals. Semin Liver Dis, 39, 86-95.
Kocot J, Dziemidok P, Kiełczykowska M, et al. (2017). Adipokine profile in patients with type 2 diabetes depends on degree of obesity. Med Sci Monit, 23, 4995–5004.
Lee SH. (2015). Adipokine profiles and metabolic health. Endocrinol Metab (Seoul), 30, 175–6.
Ouchi N., J.L. Parker, J.J. Lugus, K. Walsh (2011). Adipokines in inflammation and metabolic disease Nat. Rev. Immunol., 11 (2011), 85-97. https://doi.org/10.1038/nri2921Codoner-Franch P, Alonso-Iglesias E. (2015). Resistin: insulin resistance to malignancy. Clin Chim Acta, 438, 46–54.
Picu A, Petcu L, Ştefan S, et al. (2017). Markers of oxidative stress and antioxidant defense in Romanian patients with type 2 diabetes mellitus and obesity. Molecules, 22:E714.
Rajkovic N., Zamaklar M., . Lalic K, Jotic A., Lukic L., Milicic T., Singh S. , Stosi L., Lalic N.M. (2014). Relationship between obesity, adipocytokines and inflammatory markers in type 2 diabetes: relevance for cardiovascular risk prevention Int. J. Environ. Res. Pub. Health, 11, 4049-4065. https://doi.org/10.3390/ijerph110404049
Costandi J, Melone M, Zhao A, Rashid S. (2011). Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ Res., 108, 727–742.
Dalamaga M. (2014). Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark Med., 8, №1, 107–118.
Huang X, Yang Z. (2016). Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans. J Endocrinol Invest, 39, 607–615.
Wei Liu, Xianghai Zhou, Yufeng Li, Simin Zhang, Xiaoling Cai, Rui Zhang, Siqian Gong, Xueyao Han, Linong Ji (2020). Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus. Medicine (Baltimore), .99(6), e19052. doi: 10.1097/MD.0000000000019052
Luo et al., R. Luo, X. Li, R. Jiang, X. Gao, Z. Lü, W. Hua (2012). Serum concentrations of resistin and adiponectin and their relationship to insulin resistance in subjects with impaired glucose tolerance J. Int. Med. Res., 40, 621-630. https://doi.org/10.1177/147323001204000224
Zaidi and Shirwany, S.I.Z. Zaidi, T.A.K. Shirwany (2015). Relationship of serum resistin with insulin resistance and obesity J. Ayub. Med. Coll. Abbottabad, 27, 552-555.
Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B, Romagnani P, Milani S, Ginés P, et al. (2006) Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol, 169, 2042–2053.
Shen, C., Zhao, CY., Wang, W. et al. (2014). The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol ,14, 39. https://doi.org/10.1186/1471-230X-14-39
Van Haele M., Roskams T. (2017). Hepatic progenitor cells: an update. Gastroenterol Clin North Am, 46, 409-20.
"Inter Collegas" is an open access journal: all articles are published in open access without an embargo period, under the terms of the CC BY-NC-SA (Creative Commons Attribution ‒ Noncommercial ‒ Share Alike) license; the content is available to all readers without registration from the moment of its publication. Electronic copies of the archive of journals are placed in the repositories of the KhNMU and V.I. Vernadsky National Library of Ukraine.